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Abstract
Insertional mutagenesis has emerged as a major obstacle for gene therapy based on vectors that integrate randomly in the
genome. Reducing the genotoxicity of genomic viral integration can, in first approximation, be equated with reducing the
risk of oncogene activation, at least in the case of therapeutic payloads that have no known oncogenic potential, such as
the globin genes. An attractive solution to the problem of oncogene activation is the inclusion of insulators/enhancer-
blockers in the viral vectors. In this study we have used Recombinase-Mediated Cassette Exchange to characterize the effect
of integration of globin therapeutic cassettes in the presence or absence of the chicken HS4 and three other putative
insulators inserted near Stil, Tal1 and MAP17, three well-known cellular proto-oncogenes in the SCL/Tal1 locus. We show
that insertion of a Locus Control Region-driven globin therapeutic globin transgene had a dramatic activating effect on Tal1
and Map17, the two closest genes, a minor effect on Stil, and no effect on Cyp4x1, a non-expressed gene. Of the four
element tested, cHS4 was the only one that was able to suppress this transgene-mediated insertional transcriptional
activation. cHS4 had a strong suppressive effect on the activation expression of Map17 but has little or no effect on
expression of Tal1. The suppressive activity of cHS4 is therefore promoter specific. Importantly, the observed suppressive
effect of cHS4 on Map17 activation did not depend on its intercalation between the LCR and the Map 17 promoter. Rather,
presence of one or two copies of cHS4 anywhere within the transgene was sufficient to almost completely block the
activation of Map17. Therefore, at this complex locus, suppression of transgene-mediated insertional transcriptional
activation by cHS4 could not be adequately explained by models that predict that cHS4 can only suppress expression
through an enhancer-blocking activity that requires intercalation between an enhancer and a promoter. This has important
implications for our theoretical understanding of the possible effects of the insertion of cHS4 on gene therapy vectors. We
also show that cHS4 decreased the level of expression of the globin transgene. Therefore, the benefits of partially
preventing insertional gene activation are in part negated by the lower expression level of the transgene. A cost/benefit
analysis of the utility of incorporation of insulators in gene therapy vectors will require further studies in which the effects of
insulators on both the therapeutic gene and the flanking genes are determined at a large number of integration sites.
Identification of insulators with minimal promoter specificity would also be of great value.
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Introduction
We and others have used mouse models to provide a proof of
principle for gene therapy for the hemoglobinopathies [1–7].
Together, these studies have demonstrated that hematopoietic
stem cells (HSCs) transduced by a lentiviral vector containing a
globin gene, and transplanted to syngenic recipients can give rise
to red blood cells expressing high levels of therapeutic globin
chains. In the case of the sickle cell disease model, expression of
the corrective globins in the transduced cells reached 52% of total
hemoglobin production in 99% of the cells, a level that is sufficient
to cure the disease.
These proofs of principle are a very significant advance in the
field of gene therapy and were due to contributions by many
investigators. Of particular importance was the development of
vectors that can infect non-dividing mouse HSCs at high efficiency
and of a better virus envelope that resists centrifugal forces,
simplifying the production of concentrated viral stocks.
Since replication-defective gene therapy vectors integrate only
once, it was generally believed that they would carry minimal risks
of insertional mutagenesis in comparison with replication-compe-
tent viruses. Unfortunately, clinical trials for gene therapy of X-
SCID in France and in England that successfully treated more
than 80% of the patients have shown that the risk of mutagenesis is
not insignificant [8,9]. Insertional mutagenesis has therefore
emerged as a major obstacle for gene therapy based on vectors
that integrate randomly in the genome [10,11].
Mechanism of insertional mutagenesis
Studies in birds and mice have shown that two mechanisms
account for the large majority of cases of oncogenesis mediated by
retroviruses: the virus either encodes an oncogene or activates a
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almost always occurs by oncogene activation since very few tumor
suppressors have been found near sites of viral integration in
tumors induced by retrovirus (reviewed in [12]). Therefore, tumor
suppressor inactivation is not a major insertional mutagenesis
mechanism. As a result, reducing the risk of insertional
mutagenesis for therapeutic globin genes, which have no known
oncogenic potential, can, in first approximation, be equated with
reducing the risk of oncogene activation.
Mechanisms of gene activation by insertional
mutagenesis
The mechanisms by which genes may be activated by
insertional mutagenesis are multiple and include disruption of
negative regulatory sequences, ‘‘hijacking’’ of a coding sequence
by insertion of a viral promoter, and activation of a promoter by
insertion of a viral enhancer. The latter mechanism is by far the
most prevalent type of activation events found in animal tumors
[12], probably because it requires the least precise insertion since
enhancers can act at long distances.
Minimizing oncogene activation by enhancers carried by
therapeutic vectors should therefore be an effective method of
lowering the risks of insertional mutagenesis associated with gene
therapy. Lessening the impact of each integration event involves
understanding how highly expressed transgenes interact with their
sites of integration, and then redesigning the vectors to decrease
these interactions without drastically affecting transgene expres-
sion.
An attractive potential solution to the problem of oncogene
activation is the inclusion of insulators in the viral vectors.
Insulators are a complex class of cis-acting regulatory sequences
with at least two separable activities. The first activity, often
referred to as ‘enhancer-blocking activity’, prevents interaction
between an enhancer and a promoter. The second activity, termed
‘barrier activity’, prevents the spread of condensed chromatin into
a transcriptionally active region [13]. The best understood
insulator in vertebrates is DNase I HS4 of the LCR of the
chicken b-globin locus (cHS4) [14,15]. cHS4 is located between
the b-globin locus and an erythroid specific folate receptor gene
[16]. Chung et al. have demonstrated that cHS4 has directional
enhancer-blocking activity and barrier activity, since it protects
from position effects in a colony assay, and prevents gradual
silencing in cell culture [15,17,18].
Insulators have been shown to improve the levels of transgene
expression, but the effects on the neighboring genes have not been
adequately explored [19–25]. Theoretically, insertion of an
insulator in the genome is expected to have complex effects since
it should reduce the risk of insertional mutagenesis, but might also
disrupt endogenous regulatory elements with unpredictable effects
on gene expression. Understanding the mechanisms of action of
insulators in greater details should help us predict their effects in a
gene therapy context.
Recombinase Mediated Cassette Exchange (RMCE) is a
powerful method to compare transgenes and gene therapy
cassettes, because it can be used to site-specifically integrate
transgenes in mammalian cells [26]. We previously created a
number of RMCE integration sites termed RL1 to RL6 that can
be used to study transgene expression in mouse erythroleukemia
(MEL) cells. Integration of various cassettes at these sites of
integration has yielded a wealth of information regarding the
epigenetic mechanisms that control transgene expression, but we
had not previously studied the effect of transgenes on neighboring
genes. In collaboration with Walters et al., we reported almost 10
years ago, that as expected, the cHS4 insulator blocks enhancer-
mediated suppression of silencing in K562 cells [27] but that the
effects were complex and dependent on the site of integration. In
the current study, we have evaluated the effects of cHS4 and of
several other putative insulators on transgene expression and on
the neighboring genes at one of these previously studied RMCE
integration sites.
Results
In order to evaluate the capacity of insulators to block
insertional mutagenesis, we first inserted cassette 234-b-EGFP
on chromosome 4 at site RL5 to determine if insertion of an
expression cassette would activate the flanking genes. We chose
site RL5 (Fig. 1a) for this analysis because it is located next to three
important genes: RL5 is flanked on the left by two well-known
oncogenes, Tal1, a transcription factor that regulates hematopoi-
esis [28], and Stil, the Scl/Tal1 interrupting locus gene which is
involved in early embryonic development and in the control of cell
proliferation. On the right, RL5 is flanked by Map17 (Pdzk1ip1), a
widely expressed gene also known to be an oncogene [29], and by
Cyp4X1, a gene of the cytochrome P450 family that is expressed
at low levels in most tissues. The start sites of the Stil Tal1, Map17
and Cyp4X1 genes are respectively located 85, 24.6, 4.5 and
24 Kb from the RL5 site of integration.
We used cassette 234-b-EGFP as the reporter because we have
studied it extensively in the past and because it is similar to
cassettes that would be used for gene therapy. Cassette 234-b-
EGFP contains the miniLCR driving the human b-globin
promoter and the EGFP reporter. The miniLCR is a regulatory
element that contains DnaseI Hypersensitive sites 2, 3 and 4 of the
human b-globin Locus Control Region (LCR) a strong enhancer
that is located 6 to 20 kb upstream of the e-globin gene and that
controls the expression of all b-like globin gen [30,30–33,33]. We
[34] and others [35,36] have found that although the LCR is a
powerful regulatory element, it is subject to silencing, since 150 kb
YACs containing all the known regulatory sequences of the b-
globin gene cluster are subject to both stable and variegating
position effects in transgenic mice. The silencing is particularly
acute with the truncated LCR derivatives that must be used in
gene therapy vectors because of size constraints.
To determine the effect of cassette 234-b-EGFP on the flanking
genes, we inserted it by RMCE at site RL5. The RMCE technique
that we used is based on inverted identical Lox sites and leads to
insertion of the cassettes in both possible orientations (termed non-
permissive (N) and permissive (P) orientations). Since we have
reported before that at some sites of integration, the orientation of
the cassette plays a major role on transgene expression [37], we
used PCR to characterize the orientation of the cassette in each
clone and then selected clones with the cassette in each orientation
for further analysis. To minimize clonal variations, at least three
clones per orientation were studied.
After isolation of the targeted clones, we performed quantitative
RT-PCR experiments and FACS analysis to assess expression of
the transgene and of the four flanking genes. Five independent
transfections performed on five different days were performed. As
a control, we also inserted at RL5, a non-expressed cDNA
transgene (Figure 1B). All quantitative RT-PCR results were
normalized to expression of the b2-microglobulin gene. We then
calculated for each flanking gene, the ratio of their expression in
the presence of the 234-b-EGFP cassette and in the presence of the
non expressed cDNA (see methods).
The results are summarized in Fig. 1c and showed that insertion
of the 234-b-EGFP cassette in either orientation had a large
enhancing effect on Map17 and Tal1, the two closest genes, and a
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was not reactivated by transgene insertion.
As expected, the EGFP reporter was expressed at easily
detectable levels when cassette 234-b-EGFP was inserted at RL5.
These results suggested that RMCE at RL5 is a good
experimental system to study insulator functions since insertion
of a cassette containing regulatory elements that are necessary to
express the b-globin genes in erythroid cells leads to activation of
two of the four flanking genes.
To test insulator function, we first focused on cHS4 since it is
one of the better known insulators. We constructed three cassettes
in which the 234-b-EGFP transcription unit is flanked by a 2.4 kb
DNA segment containing two copies of the cHS4 insulator, either
in 59,i n3 9 or on both sides. We chose to focus on this duplicated
element because it has been shown to be more potent than smaller
versions [25]. The insulated cassettes were then inserted at RL5
(Fig. 2a) and expression of the flanking genes was analyzed as
above. Two to three independent transfections were performed for
each cassette and at least three clones in each orientation were
analyzed for each transfection.
The results are summarized in Fig. 2b and 2c and showed that
presence of the insulator in all three cassettes had a dramatic effect
on Map17 expression. In the presence of an insulator, levels of
Map 17 expression were 5 to 10-folds lower that when cassette
234-b-EGFP without an insulator was inserted at RL5. Impor-
tantly and unexpectedly, the results were similar whether cHS4
was located on either side of the cassette or when it was present on
both sides. Also unexpectedly, down regulation of Map17
occurred in all clones containing at least one cHS4, regardless of
the orientation of the cassette in the RL5 locus. This suggests the
cHS4 insulator can prevent activation of the Map17 promoter by
the LCR but that this cis-acting negative regulatory activity does
not require that the element be located between the enhancer and
the promoter. Presence of two flanking copies of the insulator did
not dramatically improve the ‘‘enhancer-blocking’’ effect.
Examination of expression of the Tal1 gene in the presence of the
three insulator cassettes, revealed that the cHS4 had little or no
detectable effect on Tal1 expression since that gene was over-
expressed about 10-fold when compared to the cDNA control
cassettes whether or not an insulator was present. This lack of effect
Figure 1. Insertion of cassette 234-b-EGFP activates genes near the RL5 integration site: A: Structure of the region around the RL5
integration site on chromosome 4. The integration site RL5 is located at Chr 4: position 114756771 (mouse build July 2007 (mm9) assembly). B:
Schematic of the RMCE reactions. The numbers above the gene represent the average increase in levels of expression of the flanking genes after
insertion of the 234-b-EGFP cassette at RL5. Both orientations are represented. The black triangle represents the two inverted Lox sites. Fold increases
were calculated relative to the b-2-microglobulin gene and relative to the expression of the same gene when the control cDNA cassette was inserted
at the same locus (see methods). C: Histogram summarizing the increase of the flanking genes (6standard deviation).
doi:10.1371/journal.pone.0005956.g001
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PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5956Figure 2. The cHS4 insulator block activation of Map17 but not Tal1. A: PCR analysis demonstrating insertion of 5 cassettes at RL5 in each
orientation (see methods). At least 2 clones in each orientation are shown. B and C: Schematic of the structure of RL5 loci in the presence of the
various tested cassettes in each orientation, and histograms illustrating the average activation (6standard deviation) of the flanking genes (relative to
the control cDNA cassette). D: FACS Analysis: Whisker plots of the mean linear fluorescence of 5 to 15 clones containing cassette 234-b-EGFP flanked
on either sides or on both sides by the 2.4 kb cHS4 insulator. Presence of one insulator decreases EGFP expression by more than 2-fold. Presence of 2
insulators has an even more pronounced effect. E: Histograms illustrating a Q-PCR analysis of EGFP expression of the clones analyzed by FACS in
Figure 3A. The RT-PCR results are similar to the FACS results. EGFP expression was normalized to expression of the b-2-microglobulin gene. The effect
of the insulator was independent of its location within the cassette and of the orientation of the cassette in the locus.
doi:10.1371/journal.pone.0005956.g002
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suppression of the transgene-mediated insertional activation
enhancer activity of cHS4 is promoter specific, because it can block
activation of Map17 but cannot block activation of Tal1.
Examination of EGFP expression by flow cytometry showed
that presence of an insulator decreased the expression of the
transgene 2 to 3-folds when the insulator was present on one side,
and 3 to 4-folds when the insulator was present on both sides
(Fig. 2d and 2f). Quantitative RT-PCR confirmed and extended
these results by showing that, as expected, the down regulation of
the miniLCR-b-EGFP cassette occurs at the transcriptional level.
To determine if other insulators would be more efficient than
cHS4 in this assay, we then tested three other elements: human
HS5 (hHS5), human HS4 (hHS4) and human gamma satellite
repeats. Human HS5 is the ortholog of cHS4 and has been shown
to have developmental stage specific, CTCF-mediated insulator
activity in cell culture and in transgenic mice [38,39]. Human HS4
is not an insulator and has enhancer activity. It was included in
this study because we have found that it could slow down gene
silencing at some chromosomal location (data not shown). Finally,
we tested a 1.8 kb c-satellite repeat that has recently been found to
have strong insulator activity by the Larionov lab (personal
communication, [40]). Gamma-satellite DNA has been identified
in the pericentromeric regions of human chromosomes 8, X, and
Y [41,42,43] and is composed of tandem arrays of 220 bp GC-rich
repeating units, usually forming 10–200 kb clusters flanked by a-
satellite DNA. In this study we have used a 1.8 kb DNA fragment,
termed Gamma8 (G8) that is composed of eight 220 bp diverged
monomers and that was cloned from the centromere of
chromosome 8 and that contains multiple CTCF and Ikaros
binding sites.
Cassettes containing hHS5, hHS4 and G8 sequence cloned 39
of our 234-b-EGFP, as well as controls including the uninsulated
234-b-EGFP cassette, the cDNA reference cassette and the 234-b-
EGFP-cHS4 cassettes were inserted at RL5 (Fig. 3a) and
expression of the flanking genes was assessed as described above.
Fig. 3B and 3C illustrate the results which showed that none of
these regulatory elements had any consistent cis-acting negative
regulatory or enhancer-blocking effect on activation of the Map17
or the Tal1 gene by the miniLCR. On the contrary, all three
elements seemed to have a small enhancing effect on Map17 when
they were inserted in the N orientation. Analysis of EGFP
expression by FACS (Fig. 3D and 3E) revealed that expression of
EGFP was down regulated by presence of hHS5 and hHS4. The
effects of presence of the G8 repeats were more complex (see
below).
To further examine the effect of G8 on expression of the
flanking genes, we then inserted at RL5, two cassettes in which the
G8 putative insulator was cloned on either sides and on both sides
of the 234-b-EGFP cassette. Again, G8 had no effect on expression
of the flanking genes (data not shown). We concluded from these
experiments that although the G8 mini-satellites are rich in CTCF
binding sites it has no enhancer-blocking activity.
We previously reported that expression is extremely stable at
RL5 since transgenes inserted at this site are not silenced even
after continuous culture for more than 40 passages [37]. Clones
with all of the cassettes tested in this report were passaged for at
least three months. As expected, no silencing was observed in
either orientation when the miniLCR-b-EGFP cassette alone or in
the presence of cHS4, hHS4 and hHS5 was inserted at RL5 (data
not shown). However, presence of the G8 satellites repeats led to
complete silencing after less than three months of culture when the
G8 repeats was between the Tal1 and the EGFP gene, but not
when it was between the EGFP and Map17 gene (Fig. 4A).
Quantitative RT-PCR analysis demonstrated that the silencing
occurred at the mRNA level (Fig. 4B). This demonstrates that
while the G8 repeat does not have any detectable enhancer
blocking in our assay, it does have a strong epigenetic effect on
expression.
Discussion
Insertion of transgenes at random sites of integration for gene
therapy or to create transgenic animals has long been complicated by
position effects which results either in silencing of the transgene over
time or to varying levels of gene expression. Position effects are likely
caused by the random juxtaposition of regulatory elements present in
the transgene and in the flanking sequences. We and others have
previously studied in great details expression of transgenes in the
presence of variousregulatoryelementsusingRMCE and avarietyof
othersmethodsbutrelativelyfewstudieshavefocusedontheeffectsof
transgene insertion and expression of the flanking genes. This
q u e s t i o nh a sc o m et ot h efo re f r o n ti nt h eg e n et h e r a p yf ie ldb e c a u s eo f
several reports of insertional mutagenesis.
From a theoretical point of view, insertion of an insulator or an
enhancer blocker at a random site in the genome is a double edged
sword since on one hand it should minimize activation of flanking
genes by enhancers present in the transgene, but on the other
hand, it might perturb expression of the flanking genes by
interrupting communication between endogenous regulatory
sequences. RMCE, which allows highly efficient integration of
transgenes at predefined sites of integration is particularly well
suited to address these questions.
In this study, we have tested the effect of insertion of eight
different cassettes on expression of the four genes nearest to the
RL5 site of integration. The results clearly showed that integration
of the miniLCR-b-EGFP had a dramatic activating effect on Tal1
and Map17, the two closest genes, a minor effect on Stil, and no
effect on Cyp4x1, a non-expressed gene. The effects of transgene
insertion on expression of the neighboring genes are expected to
be complex but it is likely that activation of the Tal1 and Map17
genes is largely caused by the miniLCR. This suggests that the
miniLCR can activate at least three promoters (Tal1, Map17 and
b-globin) at the same time.
The results with cHS4 are striking. This regulatory element has
a strong suppressive effect on the expression of Map17 but has
little or no effect on expression of Tal1.
Importantly, the suppression of Map17 activation did not
depend on the intercalation of cHS4 between the LCR and the
Map 17 promoter. Rather, presence of one or two copies of cHS4
anywhere within the transgene was sufficient to almost completely
eliminate the transgene-mediated insertional activation of Map17.
This result differs from previous reports [14] in which the
enhancer-blocking activity of cHS4 was defined as the ‘‘suppres-
sion of enhancer action by an element positioned between and
enhancer and a promoter’’. Formally, the suppressive activity of
cHS4 that we have detected can therefore not be called an
enhancer-blocking activity. In any case, our results clearly show
that cHS4 affects gene expression in a way that is more complex
than previously believed since the suppression of transgene-
mediated insertional activation of this element is promoter specific
and is not well described by simple directional models of enhancer-
blocking activity.
The differences between our results and previous studies are
likely due to the fact that the previous studies were based on simple
systems in which one enhancer and one promoter were tested,
while in this report multiple promoters and enhancers were
located in close proximity (see below).
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PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5956Figure 3. Insertion of hHS4, hHS5 and hG8 repeat do not block activation of Tal1 and Map17. A: PCR analysis demonstrating insertion of
the various cassettes. B and C: Diagram illustrating the structure of the RL5 region after insertion of the various cassettes and histograms summarizing
Q-RT-PCR determinations of the average fold increases (6standard deviation) of the flanking genes relative to the cDNA control cassette. The three
cassettes tested had minimal effects on expression of Tal1 and Map17. The black bars represent the fold increase of the 234-b-EGFP cassette with and
without cHS4 which was used as a control in this experiment. D and E: FACS and Q-RT-PCR analyses of EGFP expression (see Figure 3D and 3E) when
cassettes 234-b-EGFP plus hHS4, hHS5 or G8 were inserted at RL5. Levels of expression in the presence of HS5, HS4 and G8 are respectively lower or
higher than the controls both at the protein and mRNA levels.
doi:10.1371/journal.pone.0005956.g003
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number of labs. The Tal1 gene can be expressed from three
different promoters and is regulated by at least eight regulatory
regions which are used differentially in different tissues [44]. It has
also been suggested that the Tal1 and Map17 genes are co-
regulated [44].
Interestingly, interaction between the LCR, the insulator and
these regulatory regions leads to relatively constant outcomes
regardless of the orientation of the cassette in the locus and of the
linear arrangement of the regulatory elements within the
transgene: insertion of the miniLCR-b-EGFP cassette leads to
activation of Map17 and Tal1, and insertion of cHS4 blocks
activation of MAP17 but not of Tal1. We propose that at RL5, the
transgenic and the endogenous regulatory elements might interact
in three dimension and form similar structures regardless of their
linear arrangements. This hypothesis is compatible with models
that suggest that transcription occurs in factories [45] and with the
models that suggest that the LCR can form chromatin hubs
[46,47]. The mechanism of hub or loop formation has been
studied in some details fo the Drosophila gypsy insulator and at
several loci mammalian loci including the b-globin and IgF2/H19
region.
In Drosophila, loop formation is believed to involve the nuclear
lamina and the Su(Hw) complex [48,49]. In mammals, CTCF has
been shown to mediate the formation of a loop involving the
imprinting control region (ICR) and DMR1 regions that would
restrict access of the Igf2 to its enhancer [50,51]. CTCF has
recently been shown to nullify the activity of the LCR on the b-
globin gene by mediated loop formation between the LCR and
ectopically placed HS5 that was intercalated between the LCR
and the b-globin gene in transgenic mice [52]. The mechanism by
which CTCF might cause loop formation has recently been
Figure 4. Orientation-dependent silencing of b-EGFP expression in the presence of the G8 repeats. A: Dot-plots illustrating EGFP
expression of representative clones one or three months after RMCE. X-axis: forward-scatter; y-axis: FL-1 (EGFP) fluorescence. The horizontal line
represents the level of auto-fluorescence of non-tranfected control MEL cells. Presence of one copy of G8 39 of EGFP, or of two flanking copies of G8
caused silencing of the transgene in the N but not in the P orientation. B: Q-RT-PCR analysis of EGFP expression demonstrating that the silencing
induced by the G8 repeats occurs at the mRNA level.
doi:10.1371/journal.pone.0005956.g004
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cohesin, that CTCF help position cohesion on DNA and that
cohesion is required for some of the known transcriptional effects
of CTCF [53]. Recently, Wallace and Felsenfeld proposed that the
enhancer-blocking activity of cHS4 might be a corollary of a wider
role of this class of elements in organizing large scale structures
within the nucleus [14]. Our observations support this hypothesis.
However, the linear arrangement of cis-acting regulatory
elements is in some context a critical determinant of gene
expression. For instance, we previously reported that transgenes
exchanged at RL4 and RL6, two sites of integration that were
generated at the same time as the RL5 site [37], were silenced over
a 6 to 12 weeks period in an orientation-specific manner.
Similarly, we have found in the current study that presence of
the G8 repeats induces silencing at RL5 in an orientation-
dependent manner. We therefore propose that specific linear
arrangements of regulatory elements are incompatible with long
term replication of the epigenetic information necessary to keep
the chromatin in an open conformation. Stochastic progressive
silencing may be due to the formation, with a relatively high
probability, of suppressive three-dimensional structures (hubs)
which induce the formation of a permanently closed heterochro-
matin. The mechanisms that destabilize the stable replication of
the epigenetic information and lead to permanent silencing are not
completely understood but may involve transcriptional interfer-
ence and change in the timing of DNA replication as we previously
reported at other sites [54,55,56].
From a gene therapy point of view, our results suggest that
simple models of insulator and enhancer blocking function cannot
completely predict the effect of an insulated vector on the genes
near the site of integration. We demonstrated that cHS4 could be
used as an enhancer-blocker to prevent activation of Map 17, but
not of Tal1. We also show that cHS4 decreased the level of
expression of our transgene. Therefore, the potential benefit of
preventing activation of Map17 is partly negated by the lower
expression level of the transgenes. This down-regulation of the
transgene might be an idiosyncrasy of the RL5 locus since several
studies have shown that on average presence of an insulator
increases expression levels. The finding that human HS4 and HS5
and the G8 repeats can also decrease expression of the 234-b-
EGFP transgene suggests that down-regulation of EGFP when
cHS4 is 39 of the cassette is not specific to that element. A recent
study using RMCE to insert transgenes inside an intron of the
Lmo2 locus suggests that insulators decrease insertional activation
of this gene and would therefore be beneficial [57].
Nevertheless, our study suggests that insertion of an insulator in
gene therapy vectors might be associated with a cost in terms of
level of transgene expression and might not block activation of all
genes. A similar conclusion was reached by a previous study of the
same insulator in a different cell line [58]. A complete cost/benefit
analysis of the utility of incorporation of insulators in gene therapy
vectors will require further studies in which the effects of insulators
on both the therapeutic gene and the flanking genes are
determined at a large number of loci. Identification of insulators
with minimal promoter specificity would also be of great value.
Methods
RMCE
RMCE reactions were performed as previously described [37].
Briefly, RL5 cells grown in DMEM containing 10% fetal bovine
serum and 5% CO2 were selected for resistance to Hygromycin for
at least 1 week, and used for transfection while in exponential
growth phase. For each electroporation, 2610
6 cells were spun
down and resuspended in 400 ml total volume of cell culture
medium containing 25 mg of Cre expressing plasmid (SSR) and
100 mg of shuttle (targeting) plasmid (1:4). The cells were then
electroporated at 230 Volts and a capacitance of 1180 uf (Gene
Pulser Biorad) and transferred very slowly to 6-well plates
containing 10 ml of pre-warmed media. 48 h after the electropo-
ration cells were plated into 96-wells plates with Gancyclovir at
1.1 mg/ml at a concentration of 1000 to 10,000 per well. Clones
were isolated 10 days later and expanded for further analysis.
The orientation of the cassettes in each clone was determined by
PCR using the primers described in Table 1. For each cassette
studied, two primer pairs (one for each orientation) composed of
one primer annealing to the cassette and the other to the flanking
DNA at RL5 were designed so that a product would only be
created by the PCR if a site specific insertion had occurred.
Each RMCE transfection included the test cassettes plus the
cDNA cassette and the 234-b-EGFP cassette. The latter two
cassettes were used as normalization controls for each experi-
ments.
Plasmids
The components of the plasmids used in this study are described
in Table 2. The sequences of all plasmids are available on request.
The cre expression plasmid and the 234-b-EGFP cassettes have
been previously described in [37]. The 2.4 kb cHS4 double
insulator fragment was a generous gift from Dr Felsenfeld (NIH).
The 1.8 kb fragment containing the Gamma8 repeats was a
generous gift of Dr. Larionov (NIH, NCI). A portion of the cDNA
of the human ADAMTS13 gene was used as an ‘‘inert’’ control
cassette. We used a mammalian cDNA rather than a prokaryotic,
non-mammalian, or artificial DNA segment for this control
because insertion of DNA fragment with abnormal GC content
had a fairly large effect on expression at the RL5 locus (data not
shown).
RT PCR: RT-PCR reactions were done on a light-Cycler
(Roche) using 75 ng of RNA per primer pairs and using the
QuantiTect SYBR Green RT-PCR Kit. (Qiagen, Cat Number:
204243). RT-PCR conditions for all primers were: 50uC for
1200 sec (RT reaction) (slope 20uC/sec), 95uC for 900 sec
(polymerase activation) (slope 20uC/sec), followed by 36 cycles
of 94uC for 15 sec (slope 20uC/sec), 58uC for 30 sec,72uC for
30 sec (slope 2uC/sec)}. The Tm of the product was then
evaluated as follows: 95uC for 10 sec (slope 20uC/sec), 65uC for
10 sec (slope 20uC/sec),95uC for 0 sec (slope 0.1uC/sec). RT-PCR
primers are described in Table 3.
Expression of EGFP, Tal1, Map17, Stil1 and Cyp4x1 was
estimated:
1) By calculating the Delta Ct(gene of interest) (for instance
Ct(Tal1)-Ct(B2M)) for clones containing the cassette of
interest (for instance 234-b-EGFP).
2) By calculating the DeltaCt(control cassette) (for instance
Ct(tal1-Ct(B2M)) for clones containing the cDNA control
cassettes.
3) And finally by calculating the fold increase: 2exp
(-Delta Ct(gene
of interest)-DeltaCt(control cassette)).
All PCR were performed in triplicate on at least two
independent series of three clones.
FACS analysis
Flow cytometry analysis was performed 1, 2 and 3 months after
electroporation on a BD FacsCalibur (Detector,Voltage,Amp-
Gain,Mode:FSC,E1,6.31,Lin;SSC,379,1.65,Lin;FL1, 400,1, log;
Chicken HS4 Insulator
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50,000 cells were washed once in PBS with 1% FBS and
resuspended in PBS containing 1 mg/ml of Propidium Iodide.
EGFP mean linear fluorescence was normalized to the florescence
of the 234-b-EGFP cassette that had been used as a control in the
transfection and that had been cultured in parallel with the tested
Table 1. Primers to determine orientation.
plasmid PCR Primer Description NP Orientation
p232 848–425 EGFP234 P Tal1-,--EGFP-betaP-234-MM17
p232 848–437 234EGFP N Tal1-432-betaP-EGFP--.-MM17
p272 848–437 noP-EGFP N Tal1-EGFP--.-MM17
p272 848–937 noP-EGFP P Tal1-,--EGFP-MM17
p313 848–1044 234EGFPmini-HS4h N Tal1-432-betaP-EGFP--.-HS4 Mini h-MM17
p313 848–425 234EGFPmini-HS4h P Tal1-MiniHS4h-,--EGFP-beta promoter234-MM17
p346 848–938 LCR P Tal1-HS4-3-2-MM17
p415 1038–848 234EGFP-HS4c N Tal1-432-betaP-EGFP--.-HS4chicken-MM17
p415 848–1038 234EGFP-HS4c N Tal1-432-betaP-EGFP--.-HS4chicken-MM17
p415 848–425 HS4-EGFP234 P Tal1-,--HS4chicken-EGFP-betaP-234-MM17
p415 850–425 234EGFP-HS4c N Tal1-432-betaP-EGFP--.-HS4chicken-MM17
p417 848–1038 234EGFP-HS5h N Tal1-432-beta promoter-EGFP--.-HS5 human-MM17
p417 848–425 234EGFP-HS5h P Tal1-HS5 human-,--EGFP-beta promoter234-MM17
p423 848–1038 2xHS4c-EGFP-234 N Tal1-432-betaP-EGFP--.-2xHS4chicken-MM17
p423 848–425 234EGFP-2xHS4c P Tal1-,-2xHS4chicken-EGFP-betaP-234-MM17
p423 848–437 234EGFP-HS4c N Tal1-432-betaP-EGFP--.-2xHS4chicken-MM17
p423 850–425 234EGFP-2xHS4c N Tal1-432-betaP-EGFP--.-2xHS4chicken-MM17
p430 848–1042 2xHS4c-234EGFP-2xHS4c N Tal1-2xHS4chicken-432-betaP-EGFP--.-2xHS4chicken-MM17
p430 848–1070 2xHS4c-234EGFP-2xHS4c N Tal1-2xHS4chicken-432-betaP-EGFP--.-2xHS4chicken-MM17
p450 848–1021 cDNA N Tal1-cDNA-MM1
p450 848–1025 cDNA P Tal1-ANDc-MM17
p461 848–1038 EGFP-234-2xHS4c P Tal1-,--EGFP-betaP-432-2xHS4c-MM17
p461 848–1070 2xHS4c-234-EGFP P Tal1-,--EGFP-betaP-432-2xHS4c-MM17
p461 848–437 2xHS4c-234-EGFP N Tal1-2xHS4c-432-betaP-EGFP--.-MM17
p465 1038–1072 HS4 chicken P Tal1-59HS4c39-MM17
p465 848–1075 HS4 chicken N Tal1-39HS4c59-MM17
p473 848–1140 234EGFP-G8 N Tal1-G8-EGFP-betaP-234-MM17
p473 848–425 234EGFP-G8 P Tal1-432-betaP-EGFP-G8-MM17
p475 848–1138 G8-234EGFP-G8 N Tal1-G8-EGFP-betaP-234-G8-MM17
p475 8481140 G8-234EGFP-G8 P Tal1-G8-234-betaP-EGFP-G8-MM17
p475 848–1140 G8-234EGFP-G8 P Tal1-G8-234-betaP-EGFP-G8-MM17
p476 848–1138 G8-234EGFP P Tal1-EGFP-betaP-234-G8-MM17
p476 848–437 G8-234EGFP N Tal1-G8-432-betaP-EGFP-MM17
doi:10.1371/journal.pone.0005956.t001
Table 2. DNA segment inserted in the various cassettes used in this study.
Name Size (bp) Accession Number Location Freeze genomic
Human HS4 1247 Chr 11:5265030-5266276 Human May 2006
Human HS5 2652 L22754 chr:11:5267271-5269928 Human May 2006
26Chicken HS4 1211 U78775 chr1:199422885-199424103 Chicken May 2006
Gamma 8 1932 8q11.1 Human
The cHS4 insulator used in this study contained 2 tandem duplicated copies of U78775.
doi:10.1371/journal.pone.0005956.t002
Chicken HS4 Insulator
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variation of the FACS measurements since no external calibration
was used for the FacsCalibur.
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